Mineralys (NASDAQ: MLYS) CMO exercises options and sells 417 pre-planned shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom reported a small, pre-planned stock transaction. He exercised stock options covering 417 shares of common stock at $15.44 per share and sold 417 common shares at $27.55 per share under a Rule 10b5-1 trading plan adopted on October 6, 2025. Following these transactions, he directly holds 63,443 shares of common stock and 4,167 stock options, indicating this activity affected only a small portion of his overall position.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 417 shares ($11,488)
Net Sell
3 txns
Insider
Rodman David Malcom
Role
Chief Medical Officer
Sold
417 shs ($11K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 417 | $0.00 | -- |
| Exercise | Common Stock | 417 | $15.44 | $6K |
| Sale | Common Stock | 417 | $27.55 | $11K |
Holdings After Transaction:
Stock Option — 4,167 shares (Direct, null);
Common Stock — 63,860 shares (Direct, null)
Footnotes (1)
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
Key Figures
Shares sold: 417 shares
Sale price: $27.55 per share
Options exercised: 417 shares
+3 more
6 metrics
Shares sold
417 shares
Open-market sale of common stock on May 18, 2026 at $27.55
Sale price
$27.55 per share
Price for 417 Mineralys common shares sold
Options exercised
417 shares
Common stock acquired via option exercise at $15.44 per share
Exercise price
$15.44 per share
Conversion or exercise price of stock option into common stock
Shares held after
63,443 shares
Direct Mineralys common stock holdings following reported transactions
Options remaining
4,167 options
Stock options remaining after exercising 417 options; expiration March 17, 2033
Key Terms
Rule 10b5-1 trading plan, stock option, exercise or conversion of derivative security, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan financial
"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock option financial
"The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date..."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Chief Medical Officer financial
"officer_title: Chief Medical Officer"
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
FAQ
What did Mineralys Therapeutics (MLYS) Chief Medical Officer David Malcom report in this Form 4?
David Malcom reported exercising options for 417 Mineralys Therapeutics shares and selling 417 common shares. The transactions occurred on May 18, 2026, and were executed under a pre-established Rule 10b5-1 trading plan adopted on October 6, 2025.
What stock options did David Malcom exercise in Mineralys Therapeutics (MLYS)?
He exercised stock options covering 417 shares of Mineralys Therapeutics common stock at an exercise price of $15.44 per share. These options are part of a larger grant that vests 25% after one year, with the remainder vesting in 36 equal monthly installments.
Were David Malcom’s Mineralys Therapeutics (MLYS) transactions under a Rule 10b5-1 plan?
Yes. The Form 4 footnotes state the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Such plans pre-schedule trades, making the timing more routine and less indicative of short-term views.
What does the vesting schedule of David Malcom’s Mineralys Therapeutics (MLYS) stock option look like?
The option vested 25% of its underlying shares on the first anniversary of the grant date. The remaining shares vest in 36 substantially equal monthly installments thereafter, creating a gradual, time-based vesting structure for Malcom’s equity compensation.